- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Starpharma (ASX:SPL; OTCQX:SPHRY) today announced the appointment of an additional Vice President of Business Development with extensive pharmaceutical licensing experience.
Ms Eve Williamson, who will commence in the role with Starpharma in the New Year, has worked in the pharmaceutical industry for more than 20 years including senior roles in business development, marketing and sales, pricing and reimbursement, and clinical research.
Eve has spent the last 12 years in business development, during which time she was responsible for the negotiation of more than 40 licence agreements with leading international companies including Cephalon, Pfizer, Watson, Roche and Chugai.
With a strong partnering model at the core of Starpharma's commercial strategy and with multiple near-term products opportunities, Ms Williamson's skills and experience will complement the Company's already strong business development team, which in recent years has secured partnerships with leading companies including Lilly, GSK, AstraZeneca, Ansell, Okamoto and Nufarm.
Ms Williamson has worked for companies including Astra Zeneca, FH Faulding/Mayne/ Hospira and a private company, Phebra, where she was responsible for significant sales growth. At Hospira/Mayne she headed up the Business Development Team for the Asia Pacific region driving double digit growth via internal projects and an extensive licensing program. At Hospira Eve also had significant involvement in the development and launch of a number of oncology products including docetaxel.
"Eve joins Starpharma at an important and exciting period of our development," said Starpharma CEO Dr Jackie Fairley.
"The Company's dendrimer-enhanced version of docetaxel has shown enhanced efficacy and tumour targeting abilities. Eve's extensive experience in signing the deals that are critical to bringing products like this to market will ensure Starpharma remains well placed to capitalise on the huge potential we see across our portfolio of innovative drug and agrochemical candidates."
Ms Williamson is a registered Pharmacist and worked as a hospital pharmacist prior to joining industry in 1989. Eve also has a Post Graduate Diploma in Business from the University of Melbourne.
About Starpharma Holdings Limited
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.
Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and other uses. Starpharma has three core development programs: VivaGel® portfolio, drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.
Starpharma’s lead product is VivaGel® (SPL7013 Gel), a gel-based formulation of a proprietary dendrimer. VivaGel® is under clinical development for the treatment and prevention of bacterial vaginosis (BV) and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries Inc (Tokyo Stock Exchange) to market a value-added, VivaGel®-coated condom. Ansell manufactures and sells leading condom brands worldwide, including Lifestyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, the world’s second largest condom market.
In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. Partners include GSK, Lilly and AstraZeneca. In its internal program Starpharma recently announced significant tumour- targeting results in its docetaxel (Taxotere®) program, with animal studies resulting in levels of the cancer drug in tumour tissue more than 40 times greater than seen with the conventional formulation. The company is also exploring dendrimer opportunities in agrochemicals and crop protection in a series of partnerships with leading industry players including Nufarm (ASX:NUF) as well as with internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).
Forward Looking Statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.
For more information, please click here
LEVEL 13 499 ST KILDA ROAD
MELBOURNE AUSTRALIA 3004
TEL +61 3 8866 1215
MOB +61 (0) 423 139 163
Dr Jackie Fairley
Chief Executive Officer
+61 3 8532 2704
Copyright © Starpharma Holdings LimitedIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Dais Analytic Corporation Appoints Eliza Wang to Board of Directors: Company's Newest Director Brings Expertise in Commercial and Legal Matters Both in the United States and China; Joins on the Heels of Successful Business Development Trade Mission to China April 18th, 2015
Nanion Technologies Appoints James Costantin as Director of Customer Relations: Nanion is pleased to announce the appointment of Dr. James Costantin as Director of Customer Relations at Nanion Technologies Inc. March 31st, 2015